Prevalence and Factors Associated with Depression, Anxiety and Stress in IBD Patients Undergoing Intravenous Biological Therapy during the COVID-19 Pandemic-Montenegro Experience

• DOI: 10.32604/ijmhp.2022.020347
• Publication Date: 2022-05-27T08:05:11Z
• Authors: Brigita Smolović; Marija Đurović; Miloš Lukić; Marija Abramović; Damir Muhović
• Keywords: Depression; DASS; Pandemic; Montenegro

Throughout its duration, the coronavirus disease 2019 (COVID-19) pandemic has been affecting lives worldwide and had a sizeable impact on mental health, particularly for those who already suffer from chronic illnesses. Depression, Anxiety Stress (DAS) are common psychiatric comorbidities in inflammatory bowel (IBD) patients. This study aims to determine prevalence risk factors moderate severe symptoms of DAS IBD patients have undergoing intravenous biological therapy (IvBTh) during COVID-19 pandemic. The was conducted between September 1st November 30th, 2020 at Clinical Center Montenegro-IBD unit, where all Montenegro received registered IvBTh. case control consists 94 that completed validated questionnaire Score-21 (DASS-21). A total 59 tumor necrosis factor alpha inhibitors (anti-TNF therapy), while 35 anti-integrin therapy. After we calculated DASS-21 score, divided into two groups: (if they any mentioned subscale score above limit or more symptoms: higher than 14; Anxiety, 10 Stress, 19) did not significant (DASS-21 exceed limit). We also examined demographic data, data characteristics their disorders. Standard statistical processing tests were used identify Following criteria, diagnosed least depression 19.1%, anxiety 14.9% stress 20.2% multivariate analysis indicated there be statistically relation being developing depression, when suffering an active form (OR 6.487; 95% Cl 1.220–34.500, P = 0.028). Almost one third (30.9%) disorders Particular attention efforts must better focused ongoing